NGL Fine-Chem Limited: Q3 & 9M FY26 Performance Driven by Operational Efficiency and Strategic Expansion

NGL Fine-Chem Limited, a prominent player in the animal health sector, has reported a strong performance for the third quarter and nine months ended FY26. The company demonstrated significant growth across key financial and operational metrics, underscoring its robust business model and strategic initiatives. For Q3 FY26, NGL Fine-Chem recorded a revenue from operations of ₹127.51 crore, marking an impressive 43.11% year-on-year increase. This growth was complemented by a substantial improvement in profitability, with EBITDA soaring by 337.81% year-on-year to ₹22.31 crore. The EBITDA margin expanded significantly, reflecting the positive impact of easing raw material costs and enhanced operational efficiencies implemented across manufacturing processes.

The company's performance for the nine-month period also reflects this positive trend, with revenue from operations reaching ₹351.89 crore, a 28.74% increase over 9M FY25. EBITDA for 9M FY26 stood at ₹50.36 crore, growing by 91.62% year-on-year. Profit after tax (PAT) for Q3 FY26 was ₹15.69 crore, an extraordinary 1,129.12% increase year-on-year, and for 9M FY26, PAT reached ₹34.56 crore, up 70.16% year-on-year. These figures highlight NGL Fine-Chem's ability to translate revenue growth into strong bottom-line expansion.

Segmental Performance and Market Dynamics

NGL Fine-Chem's revenue mix continues to be dominated by its Animal API segment, which contributed 92% of the total revenue in Q3 FY26. Human API, Intermediates, and Formulations accounted for the remaining percentages. This strong focus on veterinary APIs positions the company as a market leader in its top products within this niche. Geographically, Asia remained the largest contributor to revenue at 38%, followed by India at 29%, and the Rest of the World (ROW) at 25%. The company's presence across diverse geographies and customer segments reflects a sustained recovery in end-market demand.

NGL Fine-Chem boasts a comprehensive product portfolio, including 40 APIs (38 Veterinary APIs and 2 Human APIs), 1 Intermediate, and 7 finished dosage forms. This broad offering, coupled with 95% in-house manufacturing and backward integrated facilities, provides a significant cost advantage and ensures high-quality products. The company's strong R&D capabilities in custom synthesis further enhance its competitive edge.

Strategic Expansion and Future Outlook

To sustain its growth trajectory, NGL Fine-Chem is actively pursuing strategic capacity expansions. The company has completed a brownfield expansion in its subsidiary Macrotech, which has added additional capacities for intermediates, with commercial production already commenced. This initiative is aimed at increasing capacities to meet growing demand.

Furthermore, NGL Fine-Chem is undertaking a significant greenfield expansion at Tarapur. This project, with an estimated capital expenditure of ₹210 crore, is designed to provide sufficient capacity to meet the demand for new products in its pipeline. Civil construction is currently underway, with ₹156 crore invested till Q3 FY26. Phase II commissioning is scheduled for Q1 FY27, and commercial production is expected to commence from the second half of FY27. The company is confident of achieving an asset turnover target of over two times from this investment, indicating strong future returns. The funding for this project will be a balanced mix of debt, capped at ₹85 crore, and internal accruals.

In parallel with its expansion plans, NGL Fine-Chem has made substantial progress on regulatory filings, crucial for future growth in controlled markets. The company has secured three Certificates of Suitability (CEPs) and submitted five additional filings. Under the European Active Substance Master File (ASMF) route, five approvals have been received alongside four new filings. These regulatory achievements bolster the company's ability to expand its market reach and product offerings.

Conclusion: Positioned for Sustained Growth

NGL Fine-Chem Limited's Q3 & 9M FY26 performance demonstrates a company that is not only delivering strong financial results but also strategically investing for future growth. With firm demand conditions, improving operational performance, and key growth investments progressing as planned, the company is well positioned to sustain its growth trajectory in the coming quarters. The focus on operational efficiencies, coupled with capacity expansions and robust regulatory progress, underpins NGL Fine-Chem's commitment to long-term value creation for its shareholders.